Anti-human immunodeficiency virus activity of a new immunosuppressant drug called Stepronin

By de Giorgi L.   Habeshaw J.A.   Broadhurst K.   Carminati P.   Oxford J.S.  

Transplantation Proceedings, Vol. 31, Iss. 8, 1999-12 ,pp. : 3257-3257

Elsevier

Access to resources Recommend Favorite

Potent antiviral activity of amprenavir in primary macrophages infected by human immunodeficiency virus

By Aquaro S.   Guenci T.   Santo F.D.   Francesconi M.   Calio R.   Perno C.F.  

Antiviral Research, Vol. 61, Iss. 2, 2004-02 ,pp. : 133-137

Elsevier

Access to resources Recommend Favorite

Patterns of in Vitro Anti-Human Immunodeficiency Virus Type 1 Antibody Production in Long-Term Nonprogressors

By Rusconi S.   Berlusconi A.   Papagno L.   Colombo M.C.   de Maddalena C.   Riva A.   Bagnarelli P.   Balotta C.   Galli M.  

Clinical Immunology, Vol. 85, Iss. 3, 1997-12 ,pp. : 320-323

Academic Press

Access to resources Recommend Favorite

Chemotherapy of Human Immunodeficiency Virus Infection

By  

Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents, Vol. 4, Iss. 1, 2004-03 ,pp. : 27-47

Bentham Science Publishers

Access to resources Recommend Favorite

Human Immunodeficiency Virus (HIV) Type-1 GP120-Specific Cell-Mediated Cytotoxicity (CMC) and Natural Killer (NK) Activity in HIV-Infected (HIV + ) Subjects: Enhancement with Interleukin-2(IL-2), IL-12, and IL-15

By Lin S.J.   Roberts R.L.   Ank B.J.   Nguyen Q.H.   Thomas E.K.   Stiehm E.R.  

Clinical Immunology, Vol. 82, Iss. 2, 1997-02 ,pp. : 163-173

Academic Press

Access to resources Recommend Favorite